Uniseed
Peter Devine serves as the Chief Executive Officer at Uniseed, a venture fund associated with leading Australian universities and the CSIRO, achieving significant capital returns through various commercial deals. In parallel, Peter holds multiple leadership roles including Chair and Non-Executive Director positions at Kinoxis Therapeutics, PERKii Enhanced Probiotics, and ProGel Microgel Technology, among others. A background in drug development is highlighted by past involvement with Spinifex Pharmaceuticals, which was acquired by Novartis for US$700 million. Peter's academic credentials include an MBA from AGSM @ UNSW and a PhD from The University of Queensland in Gynaecological Oncology.
This person is not in any teams
Uniseed
Uniseed is Australia’s longest-running venture fund, operating at the Universities of Melbourne, Queensland, Sydney & New South Wales, and the CSIRO, with investment capital provided by these research organisations and investment partners including a leading Australian Superannuation Fund, UniSuper. We are a unique commercialisation fund helping researchers from our partner research organisations turn their ideas into products and services. We support innovations that solve market problems and create a positive impact for our community. Uniseed invests over a broad range of technology sectors and has exited ten investments, to date.